|
|
|
HB5079 Engrossed |
- 2 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| is a covered service under the covered person's health |
2 |
| benefit plan, but the health carrier has determined that |
3 |
| the health care service is not covered because it does not |
4 |
| meet the health carrier's requirements for medical |
5 |
| necessity, appropriateness, health care setting, level of |
6 |
| care, or effectiveness; |
7 |
| (3) the covered person has exhausted the health |
8 |
| carrier's internal grievance process as set forth in this |
9 |
| Act; |
10 |
| (4) for appeals relating to a determination based on |
11 |
| treatment being experimental or investigational, the |
12 |
| requested health care service or treatment that is the |
13 |
| subject of the adverse determination or final adverse |
14 |
| determination is a covered benefit under the covered |
15 |
| person's health benefit plan except for the health |
16 |
| carrier's determination that the service or treatment is |
17 |
| experimental or investigational for a particular medical |
18 |
| condition and is not explicitly listed as an excluded |
19 |
| benefit under the covered person's health benefit plan with |
20 |
| the health carrier and that the covered person's health |
21 |
| care provider, who ordered or provided the services in |
22 |
| question and who is licensed under the
Medical Practice Act |
23 |
| of 1987 is a physician licensed to practice medicine in all |
24 |
| its branches , has certified that one of the following |
25 |
| situations is applicable: |
26 |
| (A) standard health care services or treatments |
|
|
|
HB5079 Engrossed |
- 3 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| have not been effective in improving the condition of |
2 |
| the covered person; |
3 |
| (B) standard health care services or treatments |
4 |
| are not medically appropriate for the covered person; |
5 |
| (C) there is no available standard health care |
6 |
| service or treatment covered by the health carrier that |
7 |
| is more beneficial than the recommended or requested |
8 |
| health care service or treatment;
|
9 |
| (D) the health care service or treatment is likely |
10 |
| to be more beneficial to the covered person, in the |
11 |
| health care provider's opinion, than any available |
12 |
| standard health care services or treatments; or |
13 |
| (E) that scientifically valid studies using |
14 |
| accepted protocols demonstrate that the health care |
15 |
| service or treatment requested is likely to be more |
16 |
| beneficial to the covered person than any available |
17 |
| standard health care services or treatments; and |
18 |
| (5) the covered person has provided all the information |
19 |
| and forms required to process an external review, as |
20 |
| specified in this Act. |
21 |
| (c) Within one business day after completion of the |
22 |
| preliminary review, the health carrier shall notify the covered |
23 |
| person and, if applicable, the covered person's authorized |
24 |
| representative in writing whether the request is complete and |
25 |
| eligible for external review. If the request: |
26 |
| (1) is not complete, the health carrier shall inform |
|
|
|
HB5079 Engrossed |
- 4 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| the covered person and, if applicable, the covered person's |
2 |
| authorized representative in writing and include in the |
3 |
| notice what information or materials are required by this |
4 |
| Act to make the request complete; or |
5 |
| (2) is not eligible for external review, the health |
6 |
| carrier shall inform the covered person and, if applicable, |
7 |
| the covered person's authorized representative in writing |
8 |
| and include in the notice the reasons for its |
9 |
| ineligibility.
|
10 |
| The notice of initial determination of ineligibility shall |
11 |
| include a statement informing the covered person and, if |
12 |
| applicable, the covered person's authorized representative |
13 |
| that a health carrier's initial determination that the external |
14 |
| review request is ineligible for review may be appealed to the |
15 |
| Director by filing a complaint with the Director. |
16 |
| Notwithstanding a health carrier's initial determination |
17 |
| that the request is ineligible for external review, the |
18 |
| Director may determine that a request is eligible for external |
19 |
| review and require that it be referred for external review. In |
20 |
| making such determination, the Director's decision shall be in |
21 |
| accordance with the terms of the covered person's health |
22 |
| benefit plan and shall be subject to all applicable provisions |
23 |
| of this Act. |
24 |
| (d) Whenever a request is eligible for external review the |
25 |
| health carrier shall, within 5 business days: |
26 |
| (1) assign an independent review organization from the |
|
|
|
HB5079 Engrossed |
- 5 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| list of approved independent review organizations compiled |
2 |
| and maintained by the Director; and |
3 |
| (2) notify in writing the covered person and, if |
4 |
| applicable, the covered person's authorized representative |
5 |
| of the request's eligibility and acceptance for external |
6 |
| review and the name of the independent review organization. |
7 |
| The health carrier shall include in the notice provided to |
8 |
| the covered person and, if applicable, the covered person's |
9 |
| authorized representative a statement that the covered person |
10 |
| or the covered person's authorized representative may, within 5 |
11 |
| business days following the date of receipt of the notice |
12 |
| provided pursuant to item (2) of this subsection (d), submit in |
13 |
| writing to the assigned independent review organization |
14 |
| additional information that the independent review |
15 |
| organization shall consider when conducting the external |
16 |
| review. The independent review organization is not required to, |
17 |
| but may, accept and consider additional information submitted |
18 |
| after 5 business days. |
19 |
| (e) The assignment of an approved independent review |
20 |
| organization to conduct an external review in accordance with |
21 |
| this Section shall be made from those approved independent |
22 |
| review organizations qualified to conduct external review as |
23 |
| required by Sections 50 and 55 of this Act. |
24 |
| (f) Upon assignment of an independent review organization, |
25 |
| the health carrier or its designee utilization review |
26 |
| organization shall, within 5 business days, provide to the |
|
|
|
HB5079 Engrossed |
- 6 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| assigned independent review organization the documents and any |
2 |
| information considered in making the adverse determination or |
3 |
| final adverse determination; in such cases, the following |
4 |
| provisions shall apply: |
5 |
| (1) Except as provided in item (2) of this subsection |
6 |
| (f), failure by the health carrier or its utilization |
7 |
| review organization to provide the documents and |
8 |
| information within the specified time frame shall not delay |
9 |
| the conduct of the external review. |
10 |
| (2) If the health carrier or its utilization review |
11 |
| organization fails to provide the documents and |
12 |
| information within the specified time frame, the assigned |
13 |
| independent review organization may terminate the external |
14 |
| review and make a decision to reverse the adverse |
15 |
| determination or final adverse determination. |
16 |
| (3) Within one business day after making the decision |
17 |
| to terminate the external review and make a decision to |
18 |
| reverse the adverse determination or final adverse |
19 |
| determination under item (2) of this subsection (f), the |
20 |
| independent review organization shall notify the health |
21 |
| carrier, the covered person and, if applicable, the covered |
22 |
| person's authorized representative, of its decision to |
23 |
| reverse the adverse determination. |
24 |
| (g) Upon receipt of the information from the health carrier |
25 |
| or its utilization review organization, the assigned |
26 |
| independent review organization shall review all of the |
|
|
|
HB5079 Engrossed |
- 7 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| information and documents and any other information submitted |
2 |
| in writing to the independent review organization by the |
3 |
| covered person and the covered person's authorized |
4 |
| representative. |
5 |
| (h) Upon receipt of any information submitted by the |
6 |
| covered person or the covered person's authorized |
7 |
| representative, the independent review organization shall |
8 |
| forward the information to the health carrier within 1 business |
9 |
| day. |
10 |
| (1) Upon receipt of the information, if any, the health |
11 |
| carrier may reconsider its adverse determination or final |
12 |
| adverse determination that is the subject of the external |
13 |
| review.
|
14 |
| (2) Reconsideration by the health carrier of its |
15 |
| adverse determination or final adverse determination shall |
16 |
| not delay or terminate the external review.
|
17 |
| (3) The external review may only be terminated if the |
18 |
| health carrier decides, upon completion of its |
19 |
| reconsideration, to reverse its adverse determination or |
20 |
| final adverse determination and provide coverage or |
21 |
| payment for the health care service that is the subject of |
22 |
| the adverse determination or final adverse determination. |
23 |
| In such cases, the following provisions shall apply: |
24 |
| (A) Within one business day after making the |
25 |
| decision to reverse its adverse determination or final |
26 |
| adverse determination, the health carrier shall notify |
|
|
|
HB5079 Engrossed |
- 8 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| the covered person and if applicable, the covered |
2 |
| person's authorized representative, and the assigned |
3 |
| independent review organization in writing of its |
4 |
| decision. |
5 |
| (B) Upon notice from the health carrier that the |
6 |
| health carrier has made a decision to reverse its |
7 |
| adverse determination or final adverse determination, |
8 |
| the assigned independent review organization shall |
9 |
| terminate the external review. |
10 |
| (i) In addition to the documents and information provided |
11 |
| by the health carrier or its utilization review organization |
12 |
| and the covered person and the covered person's authorized |
13 |
| representative, if any, the independent review organization, |
14 |
| to the extent the information or documents are available and |
15 |
| the independent review organization considers them |
16 |
| appropriate, shall consider the following in reaching a |
17 |
| decision: |
18 |
| (1) the covered person's pertinent medical records; |
19 |
| (2) the covered person's health care provider's |
20 |
| recommendation; |
21 |
| (3) consulting reports from appropriate health care |
22 |
| providers and other documents submitted by the health |
23 |
| carrier, the covered person, the covered person's |
24 |
| authorized representative, or the covered person's |
25 |
| treating provider; |
26 |
| (4) the terms of coverage under the covered person's |
|
|
|
HB5079 Engrossed |
- 9 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| health benefit plan with the health carrier to ensure that |
2 |
| the independent review organization's decision is not |
3 |
| contrary to the terms of coverage under the covered |
4 |
| person's health benefit plan with the health carrier; |
5 |
| (5) the most appropriate practice guidelines, which |
6 |
| shall include applicable evidence-based standards and may |
7 |
| include any other practice guidelines developed by the |
8 |
| federal government, national or professional medical |
9 |
| societies, boards, and associations; |
10 |
| (6) any applicable clinical review criteria developed |
11 |
| and used by the health carrier or its designee utilization |
12 |
| review organization; and |
13 |
| (7) the opinion of the independent review |
14 |
| organization's clinical reviewer or reviewers after |
15 |
| considering items (1) through (6) of this subsection (i) to |
16 |
| the extent the information or documents are available and |
17 |
| the clinical reviewer or reviewers considers the |
18 |
| information or documents appropriate; and |
19 |
| (8) for a denial of coverage based on a determination |
20 |
| that the health care service or treatment recommended or |
21 |
| requested is experimental or investigational, whether and |
22 |
| to what extent: |
23 |
| (A) the recommended or requested health care |
24 |
| service or treatment has been approved by the federal |
25 |
| Food and Drug Administration, if applicable, for the |
26 |
| condition; |
|
|
|
HB5079 Engrossed |
- 10 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| (B) medical or scientific evidence or |
2 |
| evidence-based standards demonstrate that the expected |
3 |
| benefits of the recommended or requested health care |
4 |
| service or treatment is more likely than not to be |
5 |
| beneficial to the covered person than any available |
6 |
| standard health care service or treatment and the |
7 |
| adverse risks of the recommended or requested health |
8 |
| care service or treatment would not be substantially |
9 |
| increased over those of available standard health care |
10 |
| services or treatments; or |
11 |
| (C) the terms of coverage under the covered |
12 |
| person's health benefit plan with the health carrier to |
13 |
| ensure that the health care service or treatment that |
14 |
| is the subject of the opinion is experimental or |
15 |
| investigational would otherwise be covered under the |
16 |
| terms of coverage of the covered person's health |
17 |
| benefit plan with the health carrier. |
18 |
| (j) Within 5 days after the date of receipt of all |
19 |
| necessary information, the assigned independent review |
20 |
| organization shall provide written notice of its decision to |
21 |
| uphold or reverse the adverse determination or the final |
22 |
| adverse determination to the health carrier, the covered person |
23 |
| and, if applicable, the covered person's authorized |
24 |
| representative. In reaching a decision, the assigned |
25 |
| independent review organization is not bound by any claim |
26 |
| determinations reached prior to the submission of information |
|
|
|
HB5079 Engrossed |
- 11 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| to the independent review organization. In such cases, the |
2 |
| following provisions shall apply: |
3 |
| (1) The independent review organization shall include |
4 |
| in the notice: |
5 |
| (A) a general description of the reason for the |
6 |
| request for external review; |
7 |
| (B) the date the independent review organization |
8 |
| received the assignment from the health carrier to |
9 |
| conduct the external review; |
10 |
| (C) the time period during which the external |
11 |
| review was conducted; |
12 |
| (D) references to the evidence or documentation, |
13 |
| including the evidence-based standards, considered in |
14 |
| reaching its decision; |
15 |
| (E) the date of its decision; and |
16 |
| (F) the principal reason or reasons for its |
17 |
| decision, including what applicable, if any, |
18 |
| evidence-based standards that were a basis for its |
19 |
| decision.
|
20 |
| (2) For reviews of experimental or investigational |
21 |
| treatments, the notice shall include the following |
22 |
| information: |
23 |
| (A) a description of the covered person's medical |
24 |
| condition; |
25 |
| (B) a description of the indicators relevant to |
26 |
| whether there is sufficient evidence to demonstrate |
|
|
|
HB5079 Engrossed |
- 12 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| that the recommended or requested health care service |
2 |
| or treatment is more likely than not to be more |
3 |
| beneficial to the covered person than any available |
4 |
| standard health care services or treatments and the |
5 |
| adverse risks of the recommended or requested health |
6 |
| care service or treatment would not be substantially |
7 |
| increased over those of available standard health care |
8 |
| services or treatments; |
9 |
| (C) a description and analysis of any medical or |
10 |
| scientific evidence considered in reaching the |
11 |
| opinion; |
12 |
| (D) a description and analysis of any |
13 |
| evidence-based standards; |
14 |
| (E) whether the recommended or requested health |
15 |
| care service or treatment has been approved by the |
16 |
| federal Food and Drug Administration, for the |
17 |
| condition; |
18 |
| (F) whether medical or scientific evidence or |
19 |
| evidence-based standards demonstrate that the expected |
20 |
| benefits of the recommended or requested health care |
21 |
| service or treatment is more likely than not to be more |
22 |
| beneficial to the covered person than any available |
23 |
| standard health care service or treatment and the |
24 |
| adverse risks of the recommended or requested health |
25 |
| care service or treatment would not be substantially |
26 |
| increased over those of available standard health care |
|
|
|
HB5079 Engrossed |
- 13 - |
LRB096 18956 RPM 34344 b |
|
|
1 |
| services or treatments; and |
2 |
| (G) the written opinion of the clinical reviewer, |
3 |
| including the reviewer's recommendation as to whether |
4 |
| the recommended or requested health care service or |
5 |
| treatment should be covered and the rationale for the |
6 |
| reviewer's recommendation. |
7 |
| (3) In reaching a decision, the assigned independent |
8 |
| review organization is not bound by any decisions or |
9 |
| conclusions reached during the health carrier's |
10 |
| utilization review process or the health carrier's |
11 |
| internal grievance or appeals process. |
12 |
| (4) Upon receipt of a notice of a decision reversing |
13 |
| the adverse determination or final adverse determination, |
14 |
| the health carrier immediately shall approve the coverage |
15 |
| that was the subject of the adverse determination or final |
16 |
| adverse determination.
|
17 |
| (Source: P.A. 96-857, eff. 7-1-10.)
|
18 |
| Section 95. No acceleration or delay. Where this Act makes |
19 |
| changes in a statute that is represented in this Act by text |
20 |
| that is not yet or no longer in effect (for example, a Section |
21 |
| represented by multiple versions), the use of that text does |
22 |
| not accelerate or delay the taking effect of (i) the changes |
23 |
| made by this Act or (ii) provisions derived from any other |
24 |
| Public Act.
|